Reveal Genomics

Executive Summary

Reveal Genomics is a Barcelona-based precision oncology diagnostics company, founded in 2020, focused on developing innovative genomic tests to guide cancer treatment. Its lead product, HER2DX®, is a genomic assay for HER2-positive breast cancer that integrates clinical and genomic data to help clinicians select optimal therapies. HER2DX addresses a significant unmet need in identifying patients who may benefit from escalated or de-escalated treatment, potentially reducing overtreatment and costs. As a commercial-stage product, it has the potential to become a standard-of-care test in a market projected to grow with increasing adoption of precision medicine. The company operates in a competitive landscape but differentiates through its proprietary algorithm and focus on actionable insights. The company is well-positioned to capitalize on the growing demand for non-invasive, data-driven diagnostics. With ongoing validation studies and potential regulatory expansions, Reveal Genomics could see increased clinical adoption and partnership opportunities. However, as a private startup with limited disclosed financials, commercial traction remains to be proven. Catalysts include upcoming peer-reviewed publications, CE-marking for broader EU market, and potential strategic collaborations with pharmaceutical companies seeking companion diagnostics for breast cancer therapies.

Upcoming Catalysts (preview)

• Q3 2026Publication of HER2DX validation study in early-stage breast cancer80% success
• Q2 2026CE-IVD certification for EU market expansion70% success
• Q4 2026Strategic partnership with major pharma for companion diagnostic50% success